A new era in the management of psoriasis? Promises and facts

Abstract

A number of new systemic agents, collectively termed as 'biologicals,' are made available for the treatment of psoriasis. We can display cautious optimism as to the role of these new agents, provided that further studies will be conducted in reasonable time. Rates of relapse on drug withdrawal, predictive factors for treatment failure and extensive data on drug safety are additional pieces of information required. Comparative effectiveness is also of concern. Advancements in clinical research, including severity assessment and outcome measures, should parallel improvements in the understanding of the pathomechanisms of psoriasis. A number of controversial areas exist concerning the management of psoriasis, where no direct interest from pharmaceutical companies is involved. The role of interventions like education and psychological support as an adjunct to conventional treatment is just one example. Independent research networks may be required to address these controversial areas.